SynergyMed

SynergyMed has developed a cure for cancer that takes just ten minutes to administer.

This non-surgical solution has destroyed cancerous tumors in mice and dogs, and did so without damaging surrounding healthy tissue, causing cosmetic deformities, or affecting the subject’s quality of life.

SynergyMed’s solution involves a non-invasive ablation device. Ablation is a medical procedure that involves destroying or removing abnormal tissue or cells. The company has signed Letters of Intent (LOIs) from Boston Scientific and Medtronic and projects to generate $500 million in revenue within the next five years.

Team Background

Anan Copty - Chief Executive Officer

Yahya Dajani - VP of Business Development

Daniel Kacher - Director of Clinical Studies

Co-Investors